COSTI, Maria Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 37.998
EU - Europa 20.632
AS - Asia 19.105
SA - Sud America 2.740
AF - Africa 427
OC - Oceania 55
Continente sconosciuto - Info sul continente non disponibili 29
Totale 80.986
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 37.288
SG - Singapore 5.706
GB - Regno Unito 5.560
CN - Cina 5.507
IT - Italia 5.193
DE - Germania 2.626
VN - Vietnam 2.251
BR - Brasile 2.104
HK - Hong Kong 1.901
SE - Svezia 1.861
FR - Francia 1.103
RU - Federazione Russa 873
FI - Finlandia 791
KR - Corea 692
UA - Ucraina 684
BD - Bangladesh 624
IN - India 473
TR - Turchia 457
CA - Canada 408
PL - Polonia 407
ID - Indonesia 300
BG - Bulgaria 275
AR - Argentina 242
NL - Olanda 212
JP - Giappone 199
IQ - Iraq 179
MX - Messico 177
BE - Belgio 166
IE - Irlanda 146
ES - Italia 145
ZA - Sudafrica 133
LT - Lituania 113
PK - Pakistan 107
AE - Emirati Arabi Uniti 88
EC - Ecuador 84
CH - Svizzera 83
MY - Malesia 73
AT - Austria 71
CL - Cile 71
UZ - Uzbekistan 67
VE - Venezuela 64
IR - Iran 61
SA - Arabia Saudita 60
CO - Colombia 59
MA - Marocco 57
PH - Filippine 52
CZ - Repubblica Ceca 49
PY - Paraguay 49
JO - Giordania 45
AU - Australia 42
DZ - Algeria 41
KE - Kenya 40
EG - Egitto 38
PT - Portogallo 37
RO - Romania 35
TN - Tunisia 34
AZ - Azerbaigian 27
NP - Nepal 27
UY - Uruguay 27
ET - Etiopia 26
KZ - Kazakistan 26
PE - Perù 24
TW - Taiwan 23
JM - Giamaica 22
LU - Lussemburgo 22
EU - Europa 21
DO - Repubblica Dominicana 20
TH - Thailandia 20
DK - Danimarca 19
BY - Bielorussia 18
GR - Grecia 18
AL - Albania 17
CR - Costa Rica 17
HU - Ungheria 17
IL - Israele 17
BO - Bolivia 16
NO - Norvegia 15
OM - Oman 14
BH - Bahrain 13
LB - Libano 13
RS - Serbia 13
SN - Senegal 13
NZ - Nuova Zelanda 12
KG - Kirghizistan 11
PS - Palestinian Territory 11
GT - Guatemala 10
HN - Honduras 10
MD - Moldavia 10
QA - Qatar 10
LV - Lettonia 9
NI - Nicaragua 9
BA - Bosnia-Erzegovina 8
EE - Estonia 8
GE - Georgia 8
NG - Nigeria 8
PA - Panama 8
SK - Slovacchia (Repubblica Slovacca) 8
AM - Armenia 6
GA - Gabon 6
LI - Liechtenstein 6
Totale 80.866
Salva come PNG Salva come JPEG
Città #
Southend 3.800
Ashburn 3.681
Santa Clara 3.475
Singapore 3.434
Fairfield 2.984
Houston 2.382
Woodbridge 2.116
Chandler 2.090
Hong Kong 1.856
Hefei 1.778
San Jose 1.557
Frankfurt am Main 1.262
Ann Arbor 1.257
Jacksonville 1.243
Seattle 1.173
Dearborn 1.144
Cambridge 1.141
Wilmington 1.071
Nyköping 1.010
Beijing 862
Modena 833
London 792
Ho Chi Minh City 707
Council Bluffs 663
Los Angeles 649
Seoul 645
New York 601
Hanoi 517
Helsinki 511
The Dalles 436
Chicago 423
Milan 341
Princeton 289
San Diego 277
Sofia 269
Shanghai 266
Moscow 260
Lauterbourg 259
Kraków 255
Munich 234
Eugene 230
Buffalo 205
Jakarta 205
São Paulo 199
Izmir 196
Bologna 191
Boardman 182
Orem 176
Fremont 175
Redwood City 154
Rome 138
Dallas 137
Tokyo 137
Salt Lake City 136
Dublin 133
Des Moines 129
Brussels 128
Bremen 123
Warsaw 121
Da Nang 116
Parma 100
Porto Alegre 95
Denver 94
Ottawa 90
Atlanta 89
Guangzhou 89
Chennai 88
Reggio Emilia 84
Phoenix 83
Brooklyn 79
Toronto 79
Columbus 77
Haiphong 76
Tampa 76
Amsterdam 75
Elk Grove Village 73
Montreal 69
Falls Church 67
Stockholm 66
Turku 66
Kent 63
Baghdad 62
Mexico City 61
Rio de Janeiro 61
Johannesburg 59
Grafing 58
Naples 58
Manchester 57
Milwaukee 57
Tashkent 57
Belo Horizonte 55
Turin 55
Poplar 53
Verona 53
Dong Ket 52
Paris 51
Dhaka 49
Nanjing 49
Brasília 47
Norwalk 45
Totale 54.471
Salva come PNG Salva come JPEG
Nome #
Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase 1.215
STRUTTURA DEL CRISTALLO DEL COMPLESSO DI TIMIDILATO SINTETASI (TS) CON UN LIGANDO 825
TYDOCK PHARMA s.r.l. Spin Off dell'Università di Modena e Reggio Emilia che ha come fine l'attività di ricerca e sviluppo nel settore delle biotech farmaceutiche. 661
Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase 486
Spermidine/spermine N1-acetyltranferasemodulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistanthuman ovarian cancer cell lines 471
Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth 459
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells 454
An Improved Synthesis of CENTA, a Chromogenic Substrate for β-Lactamases 450
Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics 446
Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells. 443
Metodo per la funzionalizzazione sito specifica di molecole proteiche 430
2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes 429
Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase 429
Constrained dansyl derivatives reveal bacterial specificity of highly conserved Thymidylate Synthases A 426
New thymidylate synthase inhibitors induce apoptosis in melanoma cell lines 423
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase 423
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 419
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections 416
USO DI INIBITORI DELLA PTERIDINA REDUTTASI PER LA PREVENZIONE E/O IL TRATTAMENTO DI INFEZIONI PARASSITARIE 412
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform 408
Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth 408
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections 402
Internalization and stability of a thymidylate synthase peptide inhibitor in ovarian cancer cells 401
Translational repression of thymidylate synthase by targeting its mRNA 398
Enhanced anti-hyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery 397
Conveying a newly designed hydrophilic anti-human thymidylate synthase peptide to cisplatin resistant cancer cells: are pH-sensitive liposomes more effective than conventional ones? 394
Repurposing of drugs targeting yap-tead functions 392
Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology 392
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines 390
Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-beta-lactamases 385
Biochemistry: Anchors away 385
Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth 384
A condensed thiadiazolo-pyrimidine as a new efficient fluorophore. Theoretical and experimental investigation of the electronic spectra and photophysics 382
Antibacterial agent discovery using thymidylate synthase biolibrary screening 380
Structure-based studies on species-specific inhibition of thymidylate synthase 376
2′-Deoxyuridine 5′-Monophosphate Substrate Displacement in Thymidylate Synthase through 6-Hydroxy-2H-naphtho[1,8-bc]furan-2-one Derivatives 370
pH-Promoted Release of a Novel Anti-Tumour Peptide by “Stealth” Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells 370
Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides 368
Alanine Mutants of the Interface Residues of Human Thymidylate Synthase Decode Key Features of the Binding Mode of Allosteric Anticancer Peptides 368
Proteomic and bioinformatic studies for the characterization of response to pemetrexed in platinum drug resistant ovarian cancer 363
Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance 362
Decoding the structural basis for carbapenem hydrolysis by class A β- lactamases: fishing for a pharmacophore 359
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs 359
Excited-state intramolecular proton transfer in a bioactive flavonoid provides fluorescence observables for recognizing its engagement with target proteins 357
Improving specificity vs bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine 356
Allosteric Inhibition of human Thymidylate Synthase. 356
Multiligand approach to the identification of resistant strains overexpressing beta-lactamase 355
The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment 351
Structure-Based Selectivity Optimization of Piperidine–Pteridine Derivatives as Potent Leishmania Pteridine Reductase Inhibitors 349
A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells 348
ACS Medicinal Chemistry Letters. member of the Editorial Board 346
Dimer-monomer equilibrium of human thymidylate synthase monitored by fluorescence resonance energy transfer 345
A proteomic approach to investigate the mechanism of action of anticancer peptides 342
NUOVE MOLECOLE, PER USO COME AGENTI ANTITUMORALI 342
Crystal Structure of human thymidylate synthase bound to a peptide inhibitor 342
Proteomic Approach to the Detection of the Mechanism of Action of Anticancer Peptides 342
Crystal Structure of histidine-tagged human thymidylate synthase 340
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity 340
Current and Future Chemotherapy for Chagas Disease 339
Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding 337
Development of flavonoids derivatives as leads against Leishmaniasis and Trypanosomiasis-invited lecture 336
Aprepitant as anticancer drug 334
Theoretical study of electronic spectra and photophysics of uracil derivatives. 331
Development of a Focused Library of Triazole-Linked Privileged-Structure-Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections 331
Thymidylate synthase structure, function and implication in drug discovery 328
Maxwell A: F1000Prime Recommendation of Evaluation [Neres J et al., ACS Chem Biol 2014]. In F1000Prime, 09 Jan 2015; DOI: 10.3410/f.725248139.793502885. F1000Prime.com/725248139#eval793502885 328
ANTICANCER DRUGS 327
Conformational analysis of phthalein derivatives acting as thymidylate synthase inhibitors by means of 1H NMR and quantum chemical calculations 326
IN SILICO/IN VITRO APPROACHES FOR THE IDENTIFICATION OF NEW CARBAPENEMASE INHIBITORS 326
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development 326
Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To InhibitTrypanosoma bruceiPteridine Reductase in Support of Early-Stage Drug Discovery 325
Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells 322
“A step further in the discovery of phthalein derivatives as Thymidylate Synthase inhibitors” 321
Hotspots in an obligate homodimeric anticancer target. structural and functional effects of interfacial mutations in human thymidylate synthase 320
Comparative mapping of on-targets and off-targets for the discovery of anti-trypanosomatid folate pathway inhibitors 319
PTEROATE-PEPTIDE BIOCONJUGATE TARGETING THE FOLATE RECEPTOR IN HUMAN OVARIAN CANCER CELL LINES: TRANSPORT AND MECHANISM OF ACTION. 319
Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds 318
X-ray-crystallography deciphers the activity of broad spectrum boronic acid β-Lactamases inhibitors 318
The 1,10-phenanthroline ligand enhances the antiproliferative activity of dna-intercalating thiourea-pd(Ii) and-pt(ii) complexes against cisplatin-sensitive and-resistant human ovarian cancer cell lines 316
Pharmacological and toxicological evaluation of a new series of thymidylate synthase inhibitors as anticancer agents 314
Biochemical effects of riluzole on Leishmania parasites 313
Comprehensive mechanistic analysis of hits from high-throughput and docking screens against β-lactamase 312
Alternative strategies in medicinal chemistry to face drug resistance in anticancer therapy. 311
Ligand-based discovery of N-(1,3-dioxo-1H,3H-benzo[de]isochromen-5-yl)-carboxamide and sulfonamide derivatives as thymidylate synthase A inhibitors 311
Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting 311
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 310
CYCLIZATION REACTIONS OF 1,3-DIBROMOPROPAN-2-OL, 2,3-DIBROMOPROPAN-1-OL AND 1-BROMOMETHYLOXIRANE WITH 6-AMINO-2,3-DIHYDRO-2-THIOXO-4(1H)-PYRIMIDINONE 309
1H-NMR conformational studies of some phtalein derivatives acting as thymidylate synthase inhibitors 309
Homodimeric Enzymes as Drug Targets 309
The Inhibition of Extended Spectrum beta-Lactamases: Hits and Leads 307
Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth 307
Optimizing Cell Permeation of an Antibiotic Resistance Inhibitor for Improved Efficacy 306
Thymidylate synthase inhibition: A structure-based rationale for drug design 305
MITO-group Multicenter italian trials in ovarian cancer and gynecological malignancies Borad of directors-translational research group 304
Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer-US8916679 “B2 - Granted patent as second publication”. 301
Designing selective Cys-ligands to unpair the binding of the Human Transcription Enhancer Associated Domain 4 (hTEAD-4) with its modulators to halt cancer cell growth 298
Permeation through the cell membrane of a boron-based β-lactamase inhibitor. 295
Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case 295
Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity 295
SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent 295
Totale 37.385
Salva come PNG Salva come JPEG
Categoria #
all - tutte 291.117
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 291.117
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021415 0 0 0 0 0 0 0 0 0 0 0 415
2021/20225.532 246 536 330 303 243 554 249 356 626 393 1.058 638
2022/20236.300 759 759 421 608 644 884 185 602 752 102 305 279
2023/20245.634 199 276 323 410 1.987 485 280 491 137 133 369 544
2024/202514.178 599 194 423 941 2.650 1.866 983 797 1.424 647 1.694 1.960
2025/202625.262 1.684 1.167 2.026 2.914 3.775 1.802 3.236 1.299 2.412 2.468 1.681 798
Totale 81.706